Abstract
Postoperative cystoid macular oedema (CMO) is a recognised complication of cataract surgery, occurring in around 1.5% of cases. It is generally managed with topical steroids or non-steroidal anti-inflammatory medications. We present a case of a patient who developed bilateral sequential CMO following bilateral sequential cataract surgery which was non-responsive to topical therapy and worsened following sub-Tenons administration of steroid. The patient took fingolimod for multiple sclerosis both prior to and during the period of cataract surgery which is known to result in the development of macular oedema in some patients. On fingolimod cessation, the oedema resolved over a period of 5 months with good visual recovery. We present this case to inform cataract surgeons of the risk of fingolimod-associated macular oedema in patients undergoing cataract surgery and to inform neurologists of the potential need to adjust treatment for patients undergoing cataract surgery.
Reference21 articles.
1. The Cataract National Dataset electronic multi-centre audit of 55 567 operations: updating benchmark standards of care in the United Kingdom and internationally
2. Cystoid macular edema;Rotsos;Clin Ophthalmol,2008
3. European medicines agency, 2019. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya
4. Fty720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year;Salvadori;randomized controlled trial in Europe and Australasia: Am J Transpl,2006
5. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献